Nanotechnology Laboratory, College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA 30341, USA.
J Microencapsul. 2011;28(4):294-300. doi: 10.3109/02652048.2011.559287.
In this study, we formulated a microparticulate melanoma cancer vaccine via the transdermal route. The vaccine was delivered using microneedle-based Dermaroller® which is available for cosmetic purposes. Unlike subcutaneous injections, administration using microneedles is painless and in general can increase the permeability of many compounds ranging in size from small molecules to proteins and microparticles that do not normally penetrate the skin. The vaccine microparticles were taken up by the antigen presenting cells which demonstrated a strong IgG titre level of 930 ug/mL in serum samples. The formulation increased the immunogenicity of the vaccine by incorporating the antigen into an albumin matrix having a size range of around 0.63-1.4 µm which acted as a synthetic adjuvant. The animals were vaccinated with 1 prime and 4 booster doses administered every 14 days over 8 weeks duration, followed by challenge with live tumour cells which showed protection after transdermal vaccination.
在这项研究中，我们通过透皮途径制备了一种微粒黑色素瘤癌症疫苗。该疫苗使用 Dermaroller®微针给药，Dermaroller®微针可用于美容目的。与皮下注射不同，使用微针给药无痛，通常可以增加许多大小从小分子到蛋白质和微颗粒的化合物的通透性，这些化合物通常不会穿透皮肤。疫苗微粒被抗原呈递细胞摄取，在血清样本中显示出 930μg/mL 的强 IgG 效价水平。该制剂通过将抗原纳入白蛋白基质中来提高疫苗的免疫原性，白蛋白基质的大小范围约为 0.63-1.4μm，作为一种合成佐剂。动物接受了 1 次初免和 4 次加强免疫，每 14 天给药一次，持续 8 周，然后用活肿瘤细胞进行攻击，经透皮接种后显示出保护作用。
